陈敏锋，男，博士，副研究员，硕士生导师。2010年毕业于广州中医药大学中402永利集团官网，获学士学位。2015年毕业于永利集团中药学专业，获博士学位。2015年进入永利集团中西医结合博士后流动站进行博士后研究。2018年12月进入402永利集团官网工作。主持国家自然科学基金青年基金项目1项、广东省自然科学基金项目2项。以第一作者/共同第一作者在J Clinical Investigation， Theranostics，Cancer Letters等本领域权威杂志发表SCI收录论文7篇。申请PCT国际发明专利1项，获得授权国际发明专利7项（包括美国专利、日本专利、澳大利亚专利、欧洲专利、英国专利、德国专利和法国专利各1项）、授权中国发明专利3项。

研究方向：

天然产物及其衍生物靶向肿瘤血管周细胞等肿瘤微环境细胞的作用机制及创新药物发现研究。

主持的科研项目：

[1] 国家自然科学基金青年基金项目（项目编号：81803566）

[2] 广东省自然科学基金-博士启动项目（项目编号: 2017A030310453）

[3] 广东省自然科学基金-面上项目（项目编号: 2019A1515010144）

代表性论文：

[1] Chen MF^#, Lei XP^#, Shi CZ, Huang MH, Li XB, Wu BJ, Li ZQ, Han WL, Du B, Hu JY, Nie QL, Mai WQ, Ma N, Xu NH, Zhang XY, Fan CL, Hong AH, Xia MH, Luo LP, Ma AD, Li HS, Yu Q, Chen HR*, Zhang DM*, Ye WC*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest, 2017, 127(10): 3689-3701. 

[2] Lei XP^#, Chen MF^#, Huang MH, Li XB, Shi CZ, Zhang D, Luo LP, Zhang YW, Ma N, Chen HR, Liang HF, Ye WC*, Zhang DM*. Desacetylvinblastine monohydrazide disrupts tumor vessels by promoting VE-cadherin internalization. Theranostics, 2018, 8(2):384- 398. 

[3] Lei XP ^#, Chen MF ^#, Li XB, Huang MH, Nie QL, Ma N, Chen HR, Xu NH, Ye WC*, Zhang DM*. A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype. Cancer Lett, 2018, 418:239-249. 

[4] Mai WQ#, Chen MF^#, Huang MH^#, Zhong JC, Chen J, Liu XY, Deng J, Yang XX, Ye WC, Zhang RJ*, Zhou Q*, Zhang DM*. Targeting platelet-derived growth factor receptor β inhibits the proliferation and motility of human pterygial fibroblasts. Expert Opin Ther Targets. 2019;23(9):805-817.

[5] Li XB^#, Chen MF^#, Lei XP, Huang MH, Ye WC, Zhang RJ*, Zhang DM*. Luteolin inhibits angiogenesis by blocking Gas6/Axl signaling pathway. Int J Oncol, 2017, 51(2):677-685. 

[6] Lei XP^#, Chen MF^#, Nie QL^#, Hu JY, Zhuo ZJ, Yiu A, Chen HR, Xu NH, Huang MH, Ye KH, Bai LL, Ye WC*, Zhang DM*. In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathways. Am J Cancer Res, 2016, 6(4):843-858. 

[7] Lei LF^#, Chen MF^#, Wang T, He XX, Liu BX, Deng Y, Chen XJ, Li YT, Guan SY, Yao JH, Li W, Ye WC, Zhang DM*, Zhang CX*. Novel cytotoxic nine-membered macrocyclic polysulfur cembranoid lactones from the Soft Coral Sinularia sp. Tetrahedron, 2014, 70(38):6851- 6858. 

授权发明专利：

[1] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. USA patent, US14/785,547

[2] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. Australia patent, AU2014253584 B2

[3] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. Japan patent, JP6250710

[4] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. European patent, EP2987794

[5] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. Germany patent, DE602014026358.5

[6] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. French patent, FR2987794

[7] Ye Wencai, Chen Heru, Zhang Dongmei, Chen Minfeng, Xu Nanhui. Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof. British patent, FR2987794

[8] 叶文才, 陈河如, 张冬梅, 陈敏锋, 许男徽. 长春碱类衍生物及其制备方法和应用. PCT专利进入中国阶段, ZL201480022198.1 (授权)

[9] 叶文才, 张冬梅, 陈河如, 陈敏锋, 肖绪枝, 许男徽, 雷雪萍, 胡坚杨. 长春碱及其类似物的应用.中国发明专利, ZL201310738860.0 (授权)

[10] 陈河如, 叶文才, 张冬梅, 陈敏锋, 肖绪枝, 许男徽, 雷雪萍, 胡坚杨. 一种吲哚生物碱加合物及其制备方法和在制备抗肿瘤药物中的应用. 中国发明专利, ZL201310138241.8 (授权)

联系电话：020-85228916

邮箱： minfengchen@jnu.edu.cn